preprint · Zenodo (CERN European Organization for Nuclear Research) · 2025

CRB-A3: A Computational Multi-Backbone Viral Immunotherapy Platform

Birchard, David

Cited by 0Open access

Abstract

Background: Solid tumor immunotherapies achieve limited success compared to blood cancers, with checkpoint inhibitors producing 20-30% response rates versus CAR-T's 80-90% in hematologic malignancies (Ribas & Wolchok, 2018; June et al., 2018). Tumor metabolic adaptation, apoptotic resistance, and immunosuppressive microenvironments necessitate multi-modal therapeutic approaches (Vander Heiden & DeBerardinis, 2017; Hanahan & Weinberg, 2011). Oncolytic viruses offer tumor-selective delivery platforms but historically underperform as monotherapies (Kaufman et al., 2015; Lawler et al., 2017). Methods: We developed CRB-A3, a computational model of a multi-backbone viral immunotherapy platform employing three engineered vectors: Influenza A (Phase I metabolic disruption), lentivirus (Phase II apoptotic execution), and HSV-1 (Phase III immune checkpoint blockade). The platform delivers 20 therapeutic modules across sequential phases gated by stress-responsive promoters (HSP70, NF-κB) and metabolic riboswitches (lactate-responsive). Four orthogonal safety systems (split caspase-9, HSVTK, miRNA detargeting, CRISPR self-excision) provide redundant containment. We conducted probabilistic cascade modeling across patient enrichment criteria (4-criterion vs 6-criterion biomarker panels) and assessed ULTRA-A protocol enhancements: triple metabolic blockade (glycolysis, glutaminolysis, fatty acid oxidation), ferroptosis induction, tissue-resident memory T-cell (TRM) programming, and epigenetic MHC-I upregulation. Results: Base protocol achieved 54% overall response rate (ORR) in 4/4 enriched patients (hypoxia ≥0.55, metabolic activity >0.70, dual-receptor expression ≥50th percentile, lactate ≥5.0 mM; 37% patient eligibility). ULTRA-A protocol with six-criterion enrichment (adding CD8+ T-cell infiltration ≥30th percentile and immunogenicity markers: PD-L1 CPS ≥5 OR TMB ≥10 mut/Mb OR MSI-H) projected 78-82% ORR (2025% eligibility), approaching CAR-T response rates in solid tumors. Triple metabolic blockade achieved ATP <20% with 1.6× synergy; ferroptosis module produced 59.9% cell death with 1.8× apoptotic cross-amplification; TRM programming targeted 40-50% formation providing 10-100× faster local response. Discussion: Computational modeling projects CRB-A3 as potentially the first viral immunotherapy achieving CAR-T-equivalent responses in solid tumors through biological property matching and sequential therapeutic escalation. Critical limitations include: all projections derive from in silico modeling without empirical validation; module independence assumptions may miss complex interactions; six-criterion enrichment reduces eligibility to 20-25% raising access concerns; and manufacturing/safety validation remains theoretical. The multi-backbone architecture establishes a design framework for next-generation platforms addressing solid tumor challenges, though clinical translation requires extensive preclinical and phase I-III validation (5–8-year timeline, significant attrition risk). Plain Language Summary Cancer treatments that work well in blood cancers (80-90% success) often fail in solid tumors like lung or breast cancer (20-30% success). Solid tumors resist treatment by blocking immune cells and adapting to escape single-drug approaches. CRB-A3 uses three engineered viruses working in sequence: (1) modified flu virus cuts off tumor energy (24-48 hours), (2) lentivirus triggers cell death through multiple pathways (days to weeks), (3) modified herpes virus removes immune system brakes for lasting protection (weeks to months). Each virus is controlled by tumor-specific signals and includes emergency stop mechanisms. Computer models show >50× higher activity in tumors than healthy tissue. Computer testing showed 54% response with four biomarkers, improving to 78-82% with six biomarkers and five enhancements (blocking energy pathways, programming immune memory cells). This approaches blood cancer treatment success rates but in solid tumors where similar approaches typically fail. Important limitations: These are computer simulations, not patient trials. Only 20-25% of patients would qualify with all six biomarkers, raising accessibility concerns. Manufacturing three different viruses presents practical challenges. Long-term safety requires clinical testing (5-8 years). Despite limitations, this approach demonstrates how multiple engineered viruses working together might achieve durable responses in carefully selected solid tumor patients—an outcome that has remained elusive for decades.

Cite this paper

APA 7

Birchard, D. (2025). CRB-A3: A Computational Multi-Backbone Viral Immunotherapy Platform. Zenodo (CERN European Organization for Nuclear Research). https://doi.org/10.5281/zenodo.17754081

MLA 9

Birchard, David. “CRB-A3: A Computational Multi-Backbone Viral Immunotherapy Platform.” Zenodo (CERN European Organization for Nuclear Research), 2025, https://doi.org/10.5281/zenodo.17754081.

Chicago

Birchard, David. 2025. “CRB-A3: A Computational Multi-Backbone Viral Immunotherapy Platform.” Zenodo (CERN European Organization for Nuclear Research). https://doi.org/10.5281/zenodo.17754081.

Harvard

Birchard, D. (2025) ‘CRB-A3: A Computational Multi-Backbone Viral Immunotherapy Platform’, Zenodo (CERN European Organization for Nuclear Research). Available at: https://doi.org/10.5281/zenodo.17754081.

BibTeX

@misc{birchard2025computational,
  title = {{CRB-A3: A Computational Multi-Backbone Viral Immunotherapy Platform}},
  author = {Birchard, David},
  journal = {Zenodo (CERN European Organization for Nuclear Research)},
  year = {2025},
  doi = {10.5281/zenodo.17754081}
}

Made from the index record. Check names, capitalisation and page numbers against the paper. Need another style? AI for Research has over 10,000.